Sugi Predict

Sugi Predict / Compounds / SCHEMBL3868294

SCHEMBL3868294

SCHEMBL3868294

Cc1ccc(S(=O)(=O)OCCCCN(C)C(=O)OC(C)(C)C)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 2/20 0.39
▸ PSMD10 O75832 1/20 0.38
▸ STAT3 P40763 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ METAP2 P50579 1/20 0.36
▸ GPR119 Q8TDV5 3/20 0.36
▸ CA12 O43570 3/20 0.35
▸ CA1 P00915 3/20 0.35
▸ CA2 P00918 3/20 0.35
▸ CA9 Q16790 3/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ NR1D1 P20393 1/20 0.34
▸ PDK2 Q15119 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25937387 0.99 L3MBTL1 (0.38) F2PSMD10STAT3L3MBTL1METAP2
SCHEMBL25937570 0.99 L3MBTL1 (0.38) F2PSMD10STAT3L3MBTL1METAP2
SCHEMBL4017240 0.99 L3MBTL1 (0.38) F2PSMD10STAT3L3MBTL1METAP2
SCHEMBL30075379 0.99 L3MBTL1 (0.38) F2PSMD10STAT3L3MBTL1METAP2
SCHEMBL10641249 0.96 F2 (0.39) F2PSMD10STAT3METAP2GPR119
SCHEMBL1649505 0.91 F2 (0.40) F2PSMD10STAT3CA12CA1
SCHEMBL25334266 0.87 F2 (0.38) F2PSMD10STAT3CA12CA1
SCHEMBL21458406 0.87 F2 (0.38) F2PSMD10STAT3CA12CA1
SCHEMBL20548054 0.87 F2 (0.38) F2PSMD10STAT3CA12CA1
SCHEMBL21458774 0.87 F2 (0.38) F2PSMD10STAT3CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720058-A2 BIFUNCTIONAL DEGRADERS AND USES THEREOF Casma Therapeutics, Inc. (US) 2026-04-08 — — EP disclosed
US-20250032623-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. 2025-01-30 — — US disclosed
WO-2024249291-A2 BIFUNCTIONAL DEGRADERS AND USES THEREOF CASMA THERAPEUTICS, INC. (US) 2024-12-05 — — WO disclosed
WO-2024238598-A2 STAT DEGRADERS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2024-11-21 — — WO disclosed
CN-116640117-A Triazole LPAR1 antagonists and uses thereof 武汉人福创新药物研发中心有限公司 2023-08-25 — — CN disclosed
US-20230242506-A1 HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS GENENTECHT, INC. (US) 2023-08-03 — — US disclosed
WO-2023109878-A1 TRIAZASPIRO LPAR1 ANTAGONIST AND USE THEREOF 武汉人福创新药物研发中心有限公司 2023-06-22 — — WO disclosed
WO-2023059583-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2023-04-13 — — WO disclosed
EP-4114830-A1 HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS Genentech, Inc. (US) 2023-01-11 — — EP disclosed
US-20130252890-A1 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND THE USE THEREOF FOR PRODUCTION OF MEDICAMENTS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-09-26 — — US disclosed
US-20080027066-A1 Arylpiperazinyl Compounds EPIX DELAWARE, INC. 2008-01-31 — — US disclosed
EP-1592425-A4 NEW ARYLPIPERAZINYL COMPOUNDS EPIX DELAWARE INC (US) 2007-01-24 — — EP disclosed
US-20070004742-A1 Arylpiperazinyl compounds EPIX DELAWARE, INC. 2007-01-04 — — US disclosed
US-7153858-B2 Arylpiperazinyl compounds EPIX DELAWARE, INC. (US) 2006-12-26 — — US disclosed
CN-1756551-A New arylpiperazinyl compounds PREDIX PHARMACEUTICALS HOLDING (US) 2006-04-05 — — CN disclosed
EP-1592425-A2 NEW ARYLPIPERAZINYL COMPOUNDS Predix Pharmaceuticals Holdings, Inc. (US) 2005-11-09 — — EP disclosed
WO-2004069794-A9 NEW ARYLPIPERAZINYL COMPOUNDS PREDIX PHARMACEUTICALS HOLDING (US) 2004-12-09 — — WO disclosed
US-20040220192-A1 Arylpiperazinyl compounds EPIX DELAWARE, INC. 2004-11-04 — — US disclosed
WO-2004069794-A2 NEW ARYLPIPERAZINYL COMPOUNDS PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) 2004-08-19 — — WO disclosed
US-6172045-B1 COMPLEX CONTAINING 1-DESOXY-1-THIO-N-ACETYLGALACTOSAMINE NEORX CORPORATION 2001-01-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252890-A1 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND THE USE THEREOF FOR PRODUCTION OF MEDICAMENTS CYP19A1, SHBG, ESR2 F2 584/4885PSMD10 2233/4885STAT3 1587/4885
US-20080027066-A1 Arylpiperazinyl Compounds HTR5A, HTR1A, HTR2A F2 2933/4885PSMD10 3101/4885STAT3 3176/4885
US-20230242506-A1 HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS TEAD1, TEAD2, TEAD4 F2 1060/4885PSMD10 1051/4885STAT3 1748/4885
US-20250032623-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE AURKB, CDK9, AURKA F2 4039/4885PSMD10 862/4885STAT3 819/4885
US-20070004742-A1 Arylpiperazinyl compounds HTR5A, HTR1A, HTR2A F2 2933/4885PSMD10 3101/4885STAT3 3176/4885
US-20040220192-A1 Arylpiperazinyl compounds HTR5A, HTR1A, HTR2A F2 2933/4885PSMD10 3101/4885STAT3 3176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.